Louied91
6 months ago
$CANQF NHL Alumni Association partners with CanaQuest and NEEKA Health to Conduct Studies for Anxiety and Quality of Life in former NHL Players
https://www.accesswire.com/797863/nhl-alumni-association-partners-with-canaquest-and-neeka-health-to-conduct-studies-for-anxiety-and-quality-of-life-in-former-nhl-players
TORONTO, ON / ACCESSWIRE / October 31, 2023 / NHL Alumni Association (NHLAA), NEEKA Health Canada("NEEKA"),and CanaQuest Medical Corp ("CanaQuest") are pleased to announce a transformative study partnership that will investigate the efficacy of Mentanine® as a potential treatment to reduce anxiety in former NHL players.
NEEKA will lead studies on Mentanine®, a natural cannabidiol and essential fatty acid product, to evaluate the efficacy of the formulation to reduce anxiety and increase quality of life. The research will be conducted by NEEKA's extensive and expert clinical research team which has been formed by Dr. Amin Kassam, a world-renowned neurosurgeon, and Founder / Chief Executive Officer of NEEKA, and will be led by Dr. Hunter Land, Chief Scientific Officer of NEEKA.
"The demanding nature of playing the fastest game on the planet, with no out of bounds, against the best competitors in the world, can often have a tremendous toll on the physical and emotional well-being of our NHL Alumni members, and their families, in retirement," said Glenn Healy, Executive Director of the NHLAA. "Our mission at the NHLAA is to 'Honor the Past' by finding ways to support our members in the next phase of their careers. For me personally, this means having as many tools as possible at our disposal that allow us to say ‘yes we can help' when an NHL Alumni member requires assistance. This study is exactly that, another potential solution that we think could make an immeasurable difference in the lives of our members."
A substantial number of high-performing, former professional athletes have developed impairments as a result of mental and physical trauma that has resulted in overwhelming changes to their Quality of Life (QoL). The impairments can range from mood disorders, sleeping challenges, anxiety, and issues with social and work status, among many others. In some cases, this leads to limitations in their ability to cope with their environment, a term NEEKA has defined as "functional disintegration". This study will undertake the rigorous science needed to establish the medicinal value of cannabinoids when combined with other proven interventions amongst this highly afflicted group of elite athletes and potentially improve their ability to interact with family, friends, and their communities.
"Our team has witnessed the debilitating effects of mental and physical trauma on the lives of professional athletes and their families while struggling with functional disintegration," said Edward Francis, President, and Chief Operating Officer of NEEKA. "This study represents an immense opportunity to evaluate QoL indications with cannabidiol, particularly when coupled by innovative paradigms such as upstream peer support, artificial intelligence conversation entities and digital mental health intervention."
"It's an honor to be chosen as a partner by the NHLAA and NEEKA teams. This partnership will not only transform the lives of these professional athletes and their families but could be a catalyst for new discoveries," said Paul Ramsay, CEO of CanaQuest. "This decentralized and observational study will further substantiate our pre-clinical trial results and provide valuable data on the effects and efficacy of Mentanine® and the results of this study could also develop new research initiatives as alternative treatments to help former athletes with a variety of other QoL issues such as addictions, PTSD and other secondary neurological conditions".
Dr. Amin Kassam has led four neurosurgery programs over two decades, has vast clinical experience, has published over 320 peer-reviewed articles, and is widely recognized as a true leader in technology developments that advance and define next generation patient care serves as the CEO of NEEKA. NEEKA's clinical team will be led by the global thought leader in cannabinoid research, Dr. Hunter Land. Dr. Land, CSO of NEEKA, co-led the clinical development of Epidiolex (FDA approved prescription cannabidiol) for GW Pharma, has over 20 years of R&D expertise across 25 different indications, as well as over 12 years of cannabinoid-focused research.
For more information on the clinical study, visit CanaQuest and NEEKA
Louied91
8 months ago
$CANQF CANAQUEST Announces Award of European Cannabinoid Patent
https://www.accesswire.com/viewarticle.aspx?id=785136
EU Patent #19846183.2 - A NOVEL BOTANICAL AND TETRAHYDROCANNABINOL ("THC") FORMULATION FOR THE REDUCTION OF CANNABIS-INDUCED NEGATIVE NEUROPSYCHIATRIC SIDE-EFFECTS
We believe we can provide a safer alternative to other THC products providing the benefits without the negative psychiatric side effects. Pre-clinical trials have demonstrated the reversal of depression-like and schizophrenia-related symptoms, blockage of memory impairment, hyperactive activity, and gene vulnerability.
TORONTO, ON / ACCESSWIRE / September 19, 2023 / CanaQuest Medical Corp ("CanaQuest" or the "Company") (OTC:CANQF), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), is pleased to announce it was awarded a European Cannabinoid Patent, a novel Botanical and Tetrahydrocannabinol ("THC") Formulation for the reduction of cannabis-induced negative neuropsychiatric side-effects.
The formulated product is branded as Mentabinol®, which addresses various psychiatric disorders. Acute THC consumption can trigger paranoid thoughts in vulnerable individuals.
Mentabinol® - Formulation utilizing pharmaceutical-grade botanical extract, L-theanine, and THC molecules extracted from cannabis.
The Scientific Difference - based on pre-clinical trial results at Western University
THC vs Mentabinol®
For many users, THC causes:
Memory impairment and possible long-term cognitive side effects,
Depression-like and schizophrenia-related symptoms,
Anxiety and hyperactive activity,
Schizophrenia due to gene vulnerability.
Application of Mentabinol® has demonstrated in pre-clinical trials:
Reversal of depression-like and schizophrenia-related symptom effects,
Blockage of memory impairment, hyperactive activity, and gene vulnerability.
The discovery was made by a research team led by Dr. Steven Laviolette, a professor, and neuroscientist at Western University with decades of experience in the fields of mental health and cannabinoids.
Western University's Dr. Steven Laviolette said, "What we found was that by administering L-theanine along with the THC-based formulation, we were able to block several side effects of THC exposure, including changes to schizophrenia-related neurochemical pathways, and abnormalities in behaviors - including cognitive and emotional disturbances." "This will be especially beneficial for those who are taking THC for things like long-term pain, chemotherapy side effects, or reducing anxiety or depression." Western University researchers believe this formulation may mitigate this type of harm to chronic cannabis users. The team also concluded that their research provides evidence for combining the THC-based formulations with L-theanine to make them safer for both recreational and medicinal use.
Paul Ramsay, CEO and Co-Founder of CanaQuest stated, "Our patented THC-based formulation will be a catalyst to complement pending Clinical Studies and to introduce our product, branded as Mentabinol®, to the market as a safer alternative to THC by itself."
Physicians, psychiatrists, and healthcare practitioners, interested in joining our network, as well as institutions, clinics, and pharmacies, can register via Join our network.
Domestic and international medical product distributors are welcome to contact us with indications of interest.
For more information, visit https://www.canaquest.com/corporate-profile/about-us/.
AskMuncher
3 years ago
$CANQF CANAQUEST SIGNS MEDICINAL CANNABIS EDUCATION PARTNERSHIP WITH THE CANADIAN CANNABIS DISPUTE RESOLUTION CENTRE
Press Release | 03/11/2021
TORONTO, March 11, 2021 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), is pleased to announce its new partnership with the Canadian Cannabis Dispute Resolution Centre ("CCDRC"), a national organization that has developed cannabis-related education and training programs, both domestically and internationally, to assist different levels of government, the private sector, industry-specific organizations and associations.
The CCDRC/CanaQuest partnership will serve to raise global awareness. The common theme of all education relates to conflict resolution, which can be mitigated through education. A critical component of the partnership will be its focus on promoting scientifically backed evidence, pre-clinical data and published research papers of Dr. Steven Laviolette and his 13-person team at Western University in Canada.
For the past 20 years, Dr. Laviolette and team have studied the effects of cannabinoids on mental health and wellness. Their research focuses on using cannabinoids for the development of novel pharmacotherapies to address anxiety, depression, addiction, schizophrenia and Post Traumatic Stress Disorder (PTSD).
Treena Reilkoff, a Trauma Informed Mediator and Facilitator with the CCDRC stated, “We are pleased to have the opportunity to collaborate with CanaQuest. Our common goal is the recognition that medicinal cannabis is an alternative treatment to traditional pharmaceuticals and through education about the practicality and safety of medicinal cannabis, barriers and stigmas are reduced. The CCDRC is pleased to provide education and consulting services to help prevent cannabis-related workplace conflicts from escalating.”
Paul Ramsay, CanaQuest Co-founder and President, added, “Our joint recognition of the importance of education and of people being able to have self-determination in their choices of prescriptions are the key drivers of this partnership.“
About CanaQuest Medical Corp:
CanaQuest Medical Corp is a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade). The Company is the industry partner for research and product development with Dr. Steven Laviolette, a professor and neuroscientist, who has 20 years of research experience in the field of mental health and cannabinoids and oversees a team of 13 scientists at Western University. The Company’s research is focused on the use of cannabinoids for the development of novel pharmacotherapies for mental health, such as anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder “PTSD”. CanaQuest has identified the regulatory pathways to obtain Drug Identification Numbers (DINs) for its two Master Formations, Mentanine®Rx and Mentabinol®Rx in Canada and the USA.
As well, CanaQuest will be selling both products through its wholly owned subsidiary, ADC BioMedical Corp, which was awarded a Cannabis Medical Sales, Import/Export License, from Health Canada under the Cannabis Act. Licenced GMP Contract Manufacturers in Canada and the USA, capable of formulating, processing, and packaging, have been selected for production and distribution. The Company won the Go Global Awards, 2019, "Business of the Year – Category of Life Science,” presented by the International Trade Council.
For a short video on the research, visit
For more information on CanaQuest, visit http://www.canaquest.com
About Canadian Cannabis Dispute Resolution Centre:
The Canadian Cannabis Dispute Resolution Centre is a national organization of Canadian alternative dispute resolution specialists and conflict resolution trainers with expertise in cannabis law, policy and dispute resolution. The CCDRC aspires to be an innovator in identifying practical and pre-emptive solutions to cannabis-related disputes. Its members and training partners have developed training programs that focus on conflict resolution in the cannabis field, which has included the mediation of cannabis related disputes in the areas of workplace, multi-residential structures and law enforcement. The CCDRC has also provided guidance to local and regional governments on the development of dispute resolution mechanisms and by-law creation that concerns the use and growth of cannabis in the community. This knowledge and experience will assist organizations who encounter challenges of managing and defusing internal cannabis-related conflicts that may arise from its personnel’s use of recreational cannabis, edibles, extracts and topicals and the growing presence of medicinally prescribed cannabis.
For more information on Canadian Cannabis Dispute Resolution Centre, visit
https://www.cannabisdispute.ca/about-us
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" as that term is defined in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, use of proceeds and the development, costs, and results of current or future actions and opportunities in the sector. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, our ability to raise the additional funding we will need to continue to pursue our exploration and development program, and our ability to retain important members of our management team and attract other qualified personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all the information set forth herein and should also refer to the risk factors disclosure outlined in our annual Disclosure Statement filed with the OTC Markets for the most recent fiscal year.
CANAQUEST CONTACT:
Paul Ramsay, Co-Founder & President
CanaQuest Medical Corp
paul@canaquest.com:
Tel.: 416-704-3040
CANADIAN CANNABIS DISPUTE RESOLUTION CENTRE CONTACT:
Treena Reilkoff, Trauma Informed Mediator and Facilitator
treena@cannabisdispute.ca
Tel.: 416-854-1932
AskMuncher
4 years ago
$CANQF CANAQUEST MEDICAL CORP SECURES APPROVAL FOR LISTING ON THE OCMX™, AN ONLINE INVESTOR AND FINANCIAL CONNECTION PORTAL
Press Release | 09/17/2020
TORONTO, Sept. 17, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced that it has been approved to raise capital on The OCMX™, an online portal that publicizes and provides financial connections to public and privately held investment opportunities.
Planned use of proceeds for CanaQuest’s raise include helping further facilitate a funding pathway for FDA drug approval, which is already underway.
The OCMX™ has spent considerable time completing its due diligence on the Company and concluded that there is indeed a tremendous opportunity for Investors and Advisors. The OCMX™ noted that, “CanaQuest Medical Corporation exhibits the main components of any solid investment opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.”
OCMXListing - https://theocmx.com/marketplace/canaquest/
INVESTMENT OPPORTUNITY HIGHLIGHTS
1) Based on the preclinical trial results, the Company believes that Mentanine® has several advantages compared to other CBD products. For example, the Mentanine® formula, manufacturing process and drug delivery significantly increases the efficacy of the CBD, thus requiring a lower amount of CBD for medication purposes, eliminating negative side effects associated with high CBD consumption.
2) The synergistic effect of the formula, which allows the drug to cross the Blood Brain Barrier, will provide the opportunity for Mentanine® to treat numerous mental health issues. It can also be used as a direct alternative to THC products.
3) In June 2018, Epidiolex was approved by the US FDA as the only CBD product approved by the FDA. As a result, GW Pharma generated in excess of $290 Million in revenue.
4) Under the Pharmaceutical regulatory pathway (pursued by GW Pharma), CanaQuest is focusing on obtaining approval for two scientifically developed products to deal with mental health while eliminating significant negative sides effects as compared to other CBD and THC products on the market today. Mentanine®Rx - CBD based formulation, and Mentabinol® Rx – THC based formulation. Based on pre-clinical trials results CanaQuest products have a clear path for obtaining regulatory approvals.
5) ADC Biomedical (CanaQuest’s subsidiary) will be selling medical cannabis and cannabinoid products to patients in Canada under its licence with Health Canada. Hemp-Omega (omega3 and hemp isolate) formulation will be sold to US consumers under the US Farm Bill.
About The OCMX
The OCMX™ is literally changing how companies and investment funds to generate exposure in the marketplace and raise funds as we know it. The OCMX™ serves both public and private companies along with investment and mutual funds which need to raise additional funds or gain significant market exposure. It does this by way of connecting the relevant companies, funds, investors, and advisors all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia. The OCMX™ connects investors and advisors directly with companies and investment funds seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors. The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.
About CanaQuest Medical Corp:
CanaQuest Medical Corp is a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade). The Company is the industry partner for research and product development with Dr. Steven Laviolette, a professor and neuroscientist, at Western University. The Company’s research is focused on the use of cannabinoids for the development of novel pharmacotherapies for mental health, such as anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder “PTSD”. CanaQuest’s wholly owned subsidiary, ADC BioMedical Corp, was awarded a cannabis and cannabinoid products, Sales/Purchase, Import/Export license from Health Canada for Medical purposes. The Company won the Go Global Awards, 2019, "Business of the Year – Category of Life Science,” presented by the International Trade Council.
For more information, visit http://www.canaquest.com
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" as that term is defined in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, use of proceeds and the development, costs, and results of current or future actions and opportunities in the sector. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, our ability to raise the additional funding we will need to continue to pursue our exploration and development program, and our ability to retain important members of our management team and attract other qualified personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission and OTC Markets.
CANAQUEST CONTACT:
Paul Ramsay, Co-Founder & President
CanaQuest Medical Corp
paul@canaquest.com:
Tel.: 416-704-3040
THE OCMX™ CONTACT:
The OCMX™
TD Canada Trust Tower 161 Bay Street, 45th Floor Toronto, Ontario, M5J 2S1
prosper@theocmx.com
Tel: 1-866-209-6862
AskMuncher
4 years ago
$CANQF UPDATE: CANAQUEST MEDICAL CORP FILES PROVISIONAL PATENT FOR MENTANINE® - OMEGA-3 & PURE CANNABIDIOL (“CBD”) FORMULATION BOOSTING MENTAL HEALTH EFFICACY WHILE MINIMIZING CBD DOSAGE
Press Release | 07/14/2020
TORONTO, July 14, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a company developing unique health products and nutraceuticals utilizing cannabis/hemp molecules and botanical compounds, has filed a Provisional Cannabidiol/Omega-3 Patent, trade named Mentanine®, which was developed as a result of its sponsored research program at Western University, based in London, Ontario, Canada.
The application of CBD alone has little effect/impact on the ability of the Central Nervous System “CNS” to help with mental health issues. Our newly developed formula will be a “life changer” for many.
The scientifically developed formula went through pre-clinical studies at Western University. Results from these pre-clinical trials, addressing anxiety, depression, PTSD, and schizophrenia have been statistically significant. These results also reduced inflammation, which has beneficial implications for pain. The application of this formulation can decrease opioid addiction effects and schizophrenia-related symptoms.
Mentanine® a scientifically developed and formulated medical product is tasteless and can be produced as a water-soluble liquid and powder, with significantly improved bioavailability. The liquid version of this product was produced and successfully tested for quality and safety by third party laboratories in the USA and Canada.
Dr. Laviolette (of Western University) stated, “Our CBD-based formulation works synergistically and has multiple times the efficacy compared to other CBD products on the market. This discovery sets the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects. There is strong evidence that this formulation is also a very promising epilepsy treatment, which I believe makes the formulation even more promising for these applications.”
Pre-clinical trials:
Indicated more than 10 times the efficacy as compared to CBD molecules alone
Reduced Anxiety, Depression, PTSD and Addictive effects.
Demonstrated significant reduction of inflammation, which can be beneficial for pain management.
As a result, this formulation can be administrated with significantly smaller doses of medical CBD, therefore, reducing or even eliminating the negative side effects caused by high consumption of other competing CBD oils available today.
CanaQuest has selected Licensed Processor (LP) partners for contract manufacturing in Canada and the USA to formulate, process, package and distribute Mentanine®. In Canada, the company can distribute and sell this formulation to patients and approved entities under its previously awarded Cannabis Sales/Purchase, Import/Export license from Health Canada, through its wholly owned subsidiary, ADC BioMedical Corp.
Mentanine® will be available for purchase in Canada and the USA within weeks. In order to take advantage of our exclusive introductory offer (30% discount), you can register online at www.canaqueststore.com or any questions can be sent to info@canaqueststore.com
For international distribution opportunities please contact Paul Ramsay at paul@canaquest.com
Paul Ramsay, Co-Founder and President of CanaQuest stated, “The launch of our scientifically backed product, Mentanine®, is extremally timely for patients in need, especially during these unprecedented, turbulent times. This incredible discovery opens an opportunity to treat anxiety, depression and other ailments, working side by side with THC, without getting high.”
Based on the aforementioned pre-clinical results, CanaQuest Medical is planning to register Mentanine® Rx by applying for a Drug Identification Number “DIN number” with Health Canada and the US-based Food and Drug Administration (FDA). This initiative will be done under the CanaQuest Pharma division after successful introduction of the product to the Natural Health (Nutraceutical) market. The Company believes the time to approval process will be significantly reduced because of the quality of the pre-clinical work and the recent regulatory approvals, which have been provided for other products containing CBD and THC.
The Company is also in discussions with a pharmaceutical company to formalize collaboration, production, and a distribution agreement. Simultaneously, together with other potential pharma partners, CanaQuest is in the process of organizing Human Trials to prove the efficacy and safety data following randomized double-blind, placebo-controlled trials.
Competitive Advantage
Dr. Laviolette is a scientific veteran with over 14 years of research experience in the field of mental health and cannabis and he oversees a dedicated team of 13 scientists. Dr. Laviolette’s mandate is to conduct research and pre-clinical trials to develop safe, healthy products that utilize cannabis, hemp, and botanical extracts, while blocking the negative psychiatric side-effects. All selected compounds are natural (non-synthetic).
About Dr. Steven Laviolette:
Professor and Neuroscientist at the Schulich School of Medicine & Dentistry at Western University in London, Ontario, Dr. Laviolette is a leader in the study of cannabinoids in mental health and was recently awarded “Faculty Scholar” status. Dr. Laviolette’s research team has previously made numerous fundamental discoveries related to how cannabinoids impact and may serve as treatments for mental health disorders including schizophrenia, depression, post-traumatic stress disorder and anxiety. Dr. Laviolette’s primary research focus is in characterizing how specific phytochemical derivatives of cannabis may interact with specific brain pathways and molecular mechanisms whereby they may improve symptoms associated with various mental health disorders. Research from Dr. Laviolette’s team has been published in the world’s top tier of neuroscience and psychiatry journals. The following is a link to Dr. Laviolette’s profile on Western University’s website.
http://www.schulich.uwo.ca/anatomy/people/bios/faculty/laviolette_steve.html
About CanaQuest Medical Corp:
CanaQuest Medical Corp is a life science company focused on unique health products and nutraceuticals utilizing cannabis/hemp molecules and botanical compounds, including algae compounds. The Company has engaged two prestigious Canadian universities to research and develop formulated products, which the company is in the process of launching. Our research is focused on the use of cannabis derivatives for the development of our novel pharmacotherapies for mental health, such as anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder “PTSD”. CanaQuest previously announced it filed an International Patent on Mentabinol® (THC based, all-natural formulation) as a safer alternative to all other THC products, addressing anxiety, depression and schizophrenia, while protecting all THC users from negative psychiatric side-effects. The Company won the Go Global Awards, 2019, "Business of the Year – Category of Life Science,” presented by the International Trade Council.
For more information, visit http://www.canaquest.com
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" as that term is defined in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, use of proceeds and the development, costs, and results of current or future actions and opportunities in the sector. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, our ability to raise the additional funding we will need to continue to pursue our exploration and development program, and our ability to retain important members of our management team and attract other qualified personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission and OTC Markets.
CANAQUEST CONTACT:
Paul Ramsay, Co-Founder & President
CanaQuest Medical Corp
paul@canaquest.com: Tel.: 416-704-3040
Attachment
CANAQUEST MEDICAL CORP
deri21
4 years ago
CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a developer of novel health products utilizing cannabis, hemp, and botanical extracts, including algae oils, today announced it has applied to Health Canada for approval to produce, sell and export Mentabinol® (THC based, all-natural formulation) under the Cannabis Act.
Approval of the filed application is anticipated in March 2020 and will enable CanaQuest and its Licensed Processor partners, who are capable of formulating, processing, packaging and distribution throughout Canada to initiate sales and global exports 30 days after approval. CanaQuest was awarded a Cannabis Sales/Purchase, Import/Export license from Health Canada through its wholly owned subsidiary ADC BioMedical Corp.
Positive data from CanaQuest’s research and pre-clinical trials is the driver for its first product, Mentabinol®. CanaQuest previously filed an International Patent for Mentabinol®, a Medical Cannabis formulated alternative to other THC products, which addresses anxiety, depression and schizophrenia, while protecting THC users from negative psychiatric side-effects.
Additionally, the Company is in the process of filing an application to get a Drug Identification Number (DIN) for Mentabinol Rx® with Health Canada, under The Food & Drug Act (FDA).
CanaQuest is also beginning discussions with domestic and international Pharma companies to formalize collaboration, production and distribution agreements. With potential Pharma partners, the Company plans to organize Human Trials to prove the efficacy and safety data of Mentabinol Rx® following randomized double-blind, placebo-controlled trials.
The duration of these trials is estimated to be completed within 20 weeks and will be conducted in conjunction with enrolled hospital and clinic patients suffering from anxiety and depression.
Competitive Advantage
The Company has engaged two prestigious Canadian universities to research and develop formulated products. Dr. Steven Laviolette and his team at Western University have developed two master Medical Cannabis formulations. Dr. Laviolette is a neuroscientist and scientific veteran with over 14 years of research experience in the field of mental health and cannabis and has a dedicated scientific team of 13 scientists at Western University.
This partnership gives CanaQuest a tremendous product development resource in the Medical Cannabis sector. The completed pre-clinical lab trials have previously demonstrated compelling results for both THC- and CBD-based products.
About CanaQuest Medical Corp:
CanaQuest Medical Corp is a life science company focused on medical cannabis products. The Company is committed to developing novel health products that utilize cannabis, hemp, and botanical extracts, including algae oils. The Company has engaged two prestigious Canadian universities to research and develop formulated products, which the company is in the process of launching. Our research is focused on the use of cannabis derivatives for the development of our novel pharmacotherapies for mental health, such as anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder “PTSD”. CanaQuest filed an International Patent on its first game changing discovery, Mentabinol®.
For more information, visit the CanaQuest website at http://www.canaquest.com
deri21
5 years ago
$CANQF
CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”) announces that it has won the Go Global Awards "Business of the Year – Category of Life Science”, presented by the International Trade Council.
The final judging took place during the Think Global Conference on October 22nd and 23rd in Chicago. This recognition will further open doors for international business opportunities. CanaQuest presented before a select judging panel and an audience of CEOs, investors and Government Ministers and Ambassadors. To view the presentation provided, visit http://nnw.fm/Go-Global-Awards-Presentation.
Recently, CanaQuest was granted a cannabis sales-import-export license from Health Canada. Additionally, CanaQuest filed an international patent on its first game-changing formulation, Mentabinol™, which protects THC users from negative psychotic side effects.
The Company is focused on the development of proprietary research and products utilizing cannabis oil combined with other botanical extracts, including algae oil. Positive data from CanaQuest’s research and pre-clinical trials has positioned the Company to bring its first CBD and THC based products to market.
The Company has engaged two prestigious Canadian universities, Western University and the University of Waterloo, to provide research and to create these unique formulations and products. Our research is focused on mitigation of the spread of cancerous tumors and the development of novel pharmacotherapies for mental health.
The company has found a competitive advantage working with Dr. Steve Laviolette, a scientific veteran with over 13 years of research experience in the field of mental health and cannabis, and his dedicated scientific team of 12 scientists at Western University. This partnership gives our Company a tremendous competitive advantage compared to sporadic publicly disclosed research in this area. The completed pre-clinical trials at the Western University lab have demonstrated exciting results.
“We continue to be enthusiastic about our partnership with CanaQuest, and we are proud they are winners of the Go Global Awards “Business of the Year – Category of Life Science,” states Dr. Steven Laviolette. “The results of our research have demonstrated safer and clinically superior cannabinoid formulations aimed at treating the symptoms of various mental disorders.”
Paul Ramsay, Co-Founder and President of CanaQuest, adds, “Being a winner of the Go Global Awards Business of the Year – category of Life Science, out of over 3,000 applications, is an honor and speaks highly of the tremendous accomplishments by Dr. Steven Laviolette and his team.”
About CanaQuest Medical Corp
CanaQuest Medical Corp is a life science company focused on medical cannabis products. The Company is committed to developing novel health products that utilize cannabis, hemp, and botanical extracts, including algae oils. The Company has engaged two prestigious Canadian universities to research and develop formulated products, which the company is in the process of launching. Our research is focused on the use of cannabis in the context of cancer and the use of cannabis derivatives for the development of our novel pharmacotherapies for mental health, such as anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder “PTSD”. CanaQuest was awarded a cannabis sales-import-export license from Health Canada. Additionally, CanaQuest filed an international patent on a first game changing discovery, Mentabinol™, protecting THC users from negative psychotic side effects.
For more information, visit the CanaQuest website at http://www.canaquest.com
About the International Trade Council
The International Trade Council Go Global Awards bring together hundreds of senior executives from some of the world's most innovative manufacturers, re-manufacturers and exporters, along with representatives from government bodies, trade associations, venture capital firms and financial institutions. The awards help celebrate the companies that are driving the economy forward through their innovations, technologies and strategies. While the Go Global Awards offer the opportunity to be recognized and honored by their peers it also goes beyond winning trophies and citations. The program aims to build a community of manufacturers, exporters and related service providers to support one another, share ideas, create partnerships and build on their existing knowledge and connections. Winners gain access to unique international platforms for their projects and companies throughout the extensive International Trade Council network of more than 76 countries and over 418 professional organizations worldwide.
For more information, visit the International Trade Council website at https://www.tradecouncil.org
Blunt_Buyer
5 years ago
CANAQUEST MEDICAL CORP announces Award of a
THC and CBD Research & Development at prestigious universities is the primary factor for the development of the Company’s Products.
TORONTO – September 11, 2019 - CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a company developing proprietary health products and nutraceuticals utilizing cannabinoid and botanical oil extracts,
“As a licence holder under the Cannabis Regulations, our company can now target the introduction of our first proprietary Cannabis THC and Botanical formulation, MentabinolTM after December 17th., 2019.” Paul Ramsay, Co-Founder and President of CanaQuest stated. “
Licence as permitted under the Health Canada Cannabis Act, through its wholly
owned subsidiary, ADC BioMedical Corp.
Licence is a foundation for the company to begin domestic and international sales of our
Proprietary Cannabis and Botanical formulated products.
Under the proposed Health Canada Amendment for Cannabis Edibles Regulations, our
products will be included and licenced for sale as of December 17th, 2019.
through its wholly-owned subsidiary, ADC BioMedical
Corp., has obtained a cannabis purchase/sales licence, with a provision to apply for import/export permits
for cannabis as permitted under the Health Canada Cannabis Act.
The research and pre-clinical
trials have positioned us to introduce our novel THC formulation to provide a better alternative for recreational and medicinal consumers today. Our goal is to make all consumers of THC products (recreational or medical), who are concerned about the short term and long term negative psychotic
effects of THC, aware that our products exist. There is
discovery.” Ramsay further stated.
13 years of research that has led to this amazing
The company’s competitive advantage comes from Intellectual Property developed under its sponsored research contract with Western University. Through this partnership with Dr. Laviolette, a scientific veteran with over 13 years of research in the field of mental health and cannabis, plus a dedicated scientific team of 12 scientists and Western University, CanaQuest has a definitive competitive advantage in developing Research and Science based formulations for better THC and CBD experiences. The completed pre-clinical trials at the Western University lab has demonstrated exciting results and has put the Company in a position to introduce CanaQuest’s novel THC formulation at the inception of the Edible and Extract marketplace. Additionally, the scientific data and the beneficial results of our proprietary CBD-based formulation is in the final stage and we anticipate introduction of this new formulation into the marketplace in the very near future.
http://www.schulich.uwo.ca/anatomy/people/bios/faculty/laviolette_steve.html
Cannabis Purchase/Sales
NetworkNewsWire
7 years ago
Canada’s Cannabis Market Presents Big Potential for ADYNF
In Canada, where recreational marijuana is expected to be legalized in 2018 and where registered clients are projected to increase to 715,000 by 2020 and cumulatively purchase 124,443 kg of dried medical marijuana annually, Algae Dynamics Corp. (OTCQB: ADYNF) foresees huge opportunity and greater market share. If the model seen in Colorado’s cannabis market holds true, by 2018 approximately 45 percent of Canada’s cannabis consumers will have switched from dried medical marijuana to cannabis extracts/oil. This is great news for ADYNF, which produces health products and nutraceuticals utilizing cannabis, hemp and algae oils. An article discussing this reads: “(ADYNF) is a development-stage company with a portfolio of intellectual property and a signed agreement with a Licensed Producer. ADYNF is an Ontario, Canada-based company, but it is publicly traded in the U.S. Because it is located in Canada, it is free of all exposure to any U.S. federal regulations or restrictions of cannabis. Legalization of marijuana in Canada is widely expected by July 2018 (http://nnw.fm/7DpDI). If that happens, Mackie research projects that the Canadian market for both dried marijuana and extracts/oil would be an estimated C2.8 billion in CY2018, a 30% YOY increase. By that year, sales of extracts/oil would surpass revenues from dried marijuana by C1.687 billion to C1.113 billion.”
To view the full article, visit http://nnw.fm/csE10
About Algae Dynamics Corp.
ADC is engaged in the development of unique health products and pharmaceuticals that utilize hemp, cannabis and algae oils. We have engaged two Canadian universities to provide research into the use of extracts from cannabis oil, which we plan to use to develop products that combine the significant health benefits of Omega-3s derived from algae oil and extracts from cannabis oil. Our research is focused on the use of cannabis oil in the context of cancer, and the use of cannabis derivatives for the development of novel pharmacotherapies for mental health. For more information, visit www.algaedynamics.com.
NetworkNewsWire
7 years ago
ADYNF Sees Opportunity for Hemp, Algae, and CBD Oils in Expanding Canadian Marijuana Market
- Canadian marijuana market seen as C$2.8 billion by CY2020, a 30% YOY gain, research study projects.
- Extracts/oil from cannabis (CBD) sales by CY2020 will surpass dried marijuana by wide margin.
- Marijuana seen as being fully legalized in Canada by July 2018.
Algae Dynamics Corp. (OTCQB: ADYNF) sees opportunity and greater market share in a soon to be legalized marijuana industry in Canada, where registered clients are estimated to grow to 715,000 by CY2020, cumulatively purchasing 124,443 kilograms (kg) of dried medical marijuana annually, a 31% YOY increase, a study by Mackie Research found (http://nnw.fm/9yGcp). If the Colorado model remains true, some 45% of those buyers will switch by 2018 from dried medical marijuana to marijuana extracts/oil, creating a market of 239,998 liters in extracts/oil alone.
That’s good news for ADYNF, a producer of health products and nutraceuticals that utilizes extraction of cannabis, hemp, and algae oils in its products. It is a development-stage company with a portfolio of intellectual property and a signed agreement with a Licensed Producer. ADYNF is an Ontario, Canada-based company, but it is publicly traded in the U.S. Because it is located in Canada, it is free of all exposure to any U.S. federal regulations or restrictions of cannabis.
Legalization of marijuana in Canada is widely expected by July 2018 (http://nnw.fm/7DpDI). If that happens, Mackie research projects that the Canadian market for both dried marijuana and extracts/oil would be an estimated C2.8 billion in CY2018, a 30% YOY increase. By that year, sales of extracts/oil would surpass revenues from dried marijuana by C1.687 billion to C1.113 billion.
ADYNF collaborates with the University of Waterloo and University of Western Ontario in research, formulations and product development, with the company maintaining patent rights on the research findings. The goal is to develop premium, patented health products.
Most recently, in collaboration with the University of Western Ontario, it was found that higher levels of the brain chemical GABA can help reverse in adults the negative effects of THC-infused marijuana ingested when in adolescence. The findings, published in Nature Scientific Reports (http://nnw.fm/pN6Du), earned ADYNF international press recognition.
For more information, refer to www.algaedynamics.com.
NetworkNewsWire
7 years ago
ADYNF Takes the Safe Road in Cannabis Delivery
- Focused on developing remedies from cannabis oil
- Research programs in conjunction with Universities of Waterloo & Western Ontario
- Strategy to capture market share of non-smoke MMJ nutraceuticals
To acquire the benefits of cannabis, there are many pathways, with some being distinctly safer than others. There are tinctures and topicals; there is dabbing; and there is vaping. There are drinks and digestibles and, of course, there is smoking. Over the last few decades, what some wits refer to as ‘puffing the magic dragon’ has emerged as the top delivery method for users of cannabis, but smoking harms nearly every organ of the body and causes many diseases, according to the Centers for Disease Control (CDC) (http://nnw.fm/CA7Pe). Given such adverse aftereffects, interest in safer delivery options, like those made possible by technology from Algae Dynamics Corp. (OTC: ADYNF), has grown. Algae Dynamics is an innovative biotech currently engaged in the development of nutraceuticals and pharmaceuticals utilizing hemp, cannabis and algae oils. The company plans to be a global leader in the formulation and development of health products from cannabis derivatives, algae oils and other botanical oils.
The days when inhaling and exhaling tobacco fumes was regarded as chic or sophisticated are long gone. Now that the danger from cigarettes has been laid bare, the glamour long associated with them has evaporated much as their smoke does. Smoking is responsible for about 480,000 deaths each year in the United States; that is nearly one in five deaths, a figure that exceeds the combined fatalities due to HIV, illegal drug use, alcohol, motor vehicle accidents and gun-related incidents. Notably, ‘more than 10 times as many U.S. citizens have died prematurely from cigarette smoking than have died in all the wars fought by the United States’, according to the U.S. Surgeon General (http://nnw.fm/4DSlH). These compelling statistics, together with government and private initiatives, have raised awareness of the threats posed by smoking, which extend not only to the use of tobacco but also to the newly emerging therapeutic treatments based on cannabis.
In response to the imperative for safer delivery of cannabinoids, Algae Dynamics has been working with two of Canada’s leading research universities – the University of Western Ontario and the University of Waterloo. This collaborative research is focused on the use of extracts from cannabis oil to treat some mental health issues and various forms of cancer. The program at the University of Western Ontario is studying the effects of cannabis oil on depression, post-traumatic stress disorder (PTSD), anxiety and schizophrenia, while research at the University of Waterloo is examining ways of treating colorectal, pancreas, breast and prostate cancers.
To support these research efforts, Algae Dynamics announced in August 2017 that it would be collaborating with Bonify, a Licensed Producer (LP), under the Access to Cannabis for Medical Purposes Regulations (ACMPR) in Canada, to engage in the extraction of cannabis oil, according to MarketWatch (http://nnw.fm/Cb1wu). The joint initiative entails the purchase and installation of cannabis oil extraction equipment by ADYNF at Bonify’s facility in Winnipeg, Canada. This deal will secure cannabis material for extraction and will generate revenue. As well, the cannabis oil thus produced will be supplied to the University of Waterloo and University of Western Ontario to support the Sponsored Research Agreements that ADYNF has in place with the two universities.
The market for cannabis oil is still in its embryonic stage, but it is likely to grow quickly, spurred by recent trends. A 2016 Mackie Research Capital report, extrapolating data from Colorado, one of the first U.S. states to legalize marijuana, estimates that 45 percent of dried marijuana users would eventually convert to marijuana extracts and/or oils. New Cannabis Ventures even billed cannabis extracts as ‘The Next Canadian Oil Boom’ (http://nnw.fm/a4dOI) after a court ruling allowing LPs to produce cannabis extracts. The Canadian cannabis oil extraction market is projected to grow to C$1.7 billion by 2020. With legalization for recreational use set for July 2018, safer delivery routes for cannabis therapeutics like those engineered by Algae Dynamics are sorely needed to help customers and patients avoid the hazards of smoking.
For more information, visit the company’s website at www.AlgaeDynamics.com
NetworkNewsWire
7 years ago
ADYNF Research Efforts Focus on Healthier Benefits of Cannabis Oils
- Health conscious consumers favor cannabis oil extracts and edibles over smoking
- Recent survey shows 46% of Canadians would try cannabis-infused products
- Canadian cannabis oil extraction market expected to reach $1.7 billion by 2020
Algae Dynamics Corp (OTC: ADYNF) is uniquely positioned to benefit from the upcoming legalization of recreational marijuana in Canada by mid-2018. The company’s focus on developing proprietary research and products involving botanical oils derived from cannabis combines two important consumer demands – the well-known health benefits of cannabinoids and a smoke-free alternative to cannabis consumption.
Nearly half of Canadians (46%) polled in August 2017 by Dalhousie University researchers in Nova Scotia (http://nnw.fm/93M0q) said they are interested in trying edible marijuana once recreational marijuana is legalized within the country. To clarify, medical marijuana has been legal in Canada since 2001, with some provisions, and the new law will only allow consumers to purchase dried marijuana and cannabis oil.
The preliminary study, entitled “Cannabis-infused food and Canadian consumers’ willingness to consider marijuana as a food ingredient,” was led by Dr. Sylvain Charlebois, a professor in food distribution and policy on the Faculty of Management at Dalhousie University. Among the findings, the survey shows that the majority of the 1,087 Canadians (68%) surveyed are supportive of legalizing marijuana, and cannabis-infused baked goods, cannabis oils and spices are high on the list of things to try (http://nnw.fm/9aS0X).
Algae Dynamics and its marketing team are actively preparing to respond to an increased market demand once legalization takes place. The company cites a 2016 Mackie Research Capital Corp. estimate involving trends in Colorado, one of the first U.S. states to legalize marijuana, which found that 45% of dried marijuana users would eventually convert to marijuana extracts and/or oils. Algae Dynamics’ strategy includes extracting oils from cannabis and hemp to formulate unique health and nutraceutical products, along with the distinction of becoming a leading medical cannabis producer through its association with two of Canada’s leading research universities – the University of Waterloo and the University of Western Ontario. This collaborative research is focused on the use of extracts from cannabis oil in the context of various forms of cancer, in addition to development of new pharmacotherapies for mental health.
Algae Dynamics has also signed a letter of intent with a licensed cannabis producer that has the capability to grow multiple strains of the highly regulated plant in a state-of-the-art facility. This agreement with 6779264 Manitoba Ltd., dba Bonify, gives Algae Dynamics an improved pathway to early revenues as well as a high-quality source of cannabis oil to support the research already underway at the universities.
Cannabis oils are increasingly being seen by consumers as a much healthier avenue when it comes to cannabis consumption. The Canadian government has stated its intent to delay legalization of edibles past the planned July 1, 2018, deadline (http://nnw.fm/HX66n). Instead, the government indicates that it will focus on making products like fresh or dried cannabis, cannabis oils, seeds and plants available for legal purchase.
The underserved market for licensed cannabis producers in Canada, which currently has only 59 licensed producers to serve the country’s population of 35 million, offers great potential for Algae Dynamics. As part of its strategy to be the number one Canadian cannabis research-driven product formulator, Algae Dynamics relies on a formidable leadership team of scientific and strategic advisors that complement the company’s ongoing research and development relationships and initiatives.
For more information, visit the company’s website at www.AlgaeDynamics.com
NetworkNewsWire
7 years ago
ADYNF Collaborative Study Yields Possible Breakthrough in Reversing Mental Illness Symptoms Resulting from Adolescent Cannabis Use
Algae Dynamics Corp. (OTCQB: ADYNF), a company engaged in developing unique health products and pharmaceuticals that utilize hemp, cannabis and algae oils, is making international news through its current collaboration with the University of Western Ontario (now rebranded as Western University). A recent study conducted collaboratively between the two entities and globally reported (http://nnw.fm/aJ7Oh) has found that the negative effects of tetrahydrocannabinol (THC)-rich marijuana on the adolescent brain can be reversed through the use of compounds that increase the amounts of GABA, which is a chemical and neurotransmitter in the brain. An article further discussing this reads: “THC exposure reduced the GABA in the brain, the study found. GABA regulates hyperactivity in the brain and has been associated with disorders such as schizophrenia. Negative effects developed later in adulthood from use of marijuana with THC include anxiety, depression and schizophrenia. Drugs that increase the amount of GABA could then reverse the impact of THC and eliminate the schizophrenia-linked symptoms, the research found. ‘We actually went in, and tried to restore the GABA system by activating GABA receptors directly in the prefrontal cortex,’ Western University Professor Steven Laviolette, who spearheaded the research study, said on the Andrew Lawton radio show in Canada (http://nnw.fm/07Snd). ‘To our amazement, we found that this reversed those schizophrenia-like symptoms,’ he added in an interview with CBC London. He explained that the reversal process can still remain effective many years after the exposure.”
To view the full article, visit http://nnw.fm/H4S0q
About Algae Dynamics Corp.
ADC is engaged in the development of unique health products and pharmaceuticals that utilize hemp, cannabis and algae oils. We have engaged two Canadian universities to provide research into the use of extracts from cannabis oil, which we plan to use to develop products that combine the significant health benefits of Omega-3s derived from algae oil and extracts from cannabis oil. Our research is focused on the use of cannabis oil in the context of cancer, and the use of cannabis derivatives for the development of novel pharmacotherapies for mental health. For more information, visit http://www.algaedynamics.com
NetworkNewsWire
7 years ago
ADYNF Collaborates with University of Western Ontario
- Research finds that higher levels of the brain chemical GABA can reverse negative effects such as schizophrenia and depression
- Professor Steven Laviolette, who spearheaded the study, hopes that GABA-increasing cannabinoid compounds developed with industrial partners from this research could lead to clinical trials “in the next few years”
- Algae Dynamics Corp. has signed a collaborative agreement with the University of Western Ontario, giving the company the patent rights to any drugs developed as a result of research
Algae Dynamics Corp. (OTCQB: ADYNF) is in a collaboration agreement with the University of Western Ontario (now rebranded as Western University), which is making international news with its recent study in Nature Scientific Reports (http://nnw.fm/aJ7Oh). The study found that the negative effects on the adolescent brain from chronic use of tetrahydrocannabinol (THC)-rich marijuana can be reversed by using compounds which increase the amounts of GABA, a chemical and neurotransmitter in the brain.
The article in Nature Scientific Reports is titled “Adolescent THC Exposure Causes Enduring Prefrontal Cortical Disruption of GABAergic Inhibition and Dysregulation of Sub-Cortical Dopamine Function.” The results have been globally reported by Global News, CBC of London, CTV News and UPI.
“What this could mean is that if you are going to be using marijuana, in a recreational or medicinal way, you can potentially combine it with compounds that boost GABA to block the negative effects of THC,” Professor Steven Laviolette of Western University’s Schulich School of Medicine and Dentistry told UPI (http://nnw.fm/yKuH2). Laviolette spearheaded the research study.
Laviolette has focused on the impact of nicotine and opiates and the neurobiology of addiction. He is studying the interface of neurobiology, psychology and emotion by using an integrative combination of behavioral neuropharmacology and vivo neuronal electrophysiology.
THC exposure reduced the GABA in the brain, the study found. GABA regulates hyperactivity in the brain and has been associated with disorders such as schizophrenia. Negative effects developed later in adulthood from use of marijuana with THC include anxiety, depression and schizophrenia. Drugs that increase the amount of GABA could then reverse the impact of THC and eliminate the schizophrenia-linked symptoms, the research found.
“We actually went in, and tried to restore the GABA system by activating GABA receptors directly in the prefrontal cortex,” Laviolette said on the Andrew Lawton radio show in Canada (http://nnw.fm/07Snd). “To our amazement, we found that this reversed those schizophrenia-like symptoms,” he added in an interview with CBC London. He explained that the reversal process can still remain effective many years after the exposure.
“What is important about this study is that not only have we developed a specific mechanism in the prefrontal mechanism for some of the mental health risks associated with adolescent marijuana use,” Laviolette told UPI. “But we have also identified a mechanism to reverse those risks.”
More research is needed to learn if boosting GABA levels would have the same results in humans as in rats, but Laviolette said that, to those people with mental health problems, there may be new hope. Laviolette told CTV News, “I think this is really a promising lead in terms of the potential of developing much safer versions of cannabinoid type drugs.”
Global News added that the next step is combining cannabinoid chemicals with compounds to boost the GABA system. The goal would be to determine better treatments for a range of other mental health disorders, such as anxiety, depression and addiction.
Laviolette, interviewed on the Lawton Show, explained that there is a need now to “dig further” into this research. The result could be more molecular pathways in the future to formulate pharmaceutical compounds with industrial partners, including the process of conducting clinical trials within the next few years. Compounds using cannabinoids may be developed in the future, he said. Cannabidiol can actually have the opposite effect of THC — negating the impact of THC.
He told Lawton that some ‘black market’ marijuana may contain up to 70% THC. THC can also increase dependency levels, he said. The reversal process may suggest larger treatment issues for schizophrenia, regardless of marijuana or THC use.
Forbes reported (http://nnw.fm/0OmnV) that another study found that chronic cannabis use can result in blunted stress reactivity. That study observed 40 cannabis users and 42 non-users to complete the stress or no-stress conditions of the Maastricht Acute Stress Test (MAST). Saliva samples and cannabis cravings and withdrawal were measured, as part of the study. Results indicated a link between higher stress ratings in non-users. In contrast, chronic cannabis users exhibited blunted stress reactivity, it said. Forbes inferred that marijuana compounds can reduce stress without the dependency of prescription medications.
While preliminary, Forbes explained, the study suggests that marijuana compounds may eventually be used to provide anxiety relief with decreased dependency, fewer side effects and reduced overdose potential.
ADYNF is engaged in the development of products and pharmaceuticals that use cannabis, hemp and algae oils. The development stage company is based in Canada and publicly traded in the U.S. The company has signed a collaboration agreement with the University of Western Ontario, enabling the firm to retain the rights to patents developed in conjunction with the school. Western University is focused on the areas of depression, post-traumatic stress disorder, anxiety and schizophrenia.
According to an ADYNF corporate presentation (http://nnw.fm/HNa1I), the company is building its intellectual property portfolio in the pharmaceutical field. Its goal is to develop value-added products, supported by strong science and clinical trials, combining the benefits of algae and cannabis oils to enhance efficacy in a unique and patented way.
For more information, visit the company’s website at www.AlgaeDynamics.com
NetworkNewsWire
7 years ago
ADYNF Collaborates with Prominent Neuroscientist to Research Cannabinoid Potential in Treating Mental Health Disorders
Algae Dynamics Corp. (OTCQB: ADYNF), a Canadian company engaged in developing proprietary research as well as products derived from cannabis and hemp oils, has commenced a collaborative relationship with Dr. Laviolette, a neuroscientist at the University of Western Ontario, Canada, who is examining the treatment potential of cannabinoids in addressing disorders like addiction, schizophrenia, depression and post-traumatic stress disorder. Dr. Laviolette has been seeking ways to more effectively utilize chemicals found in marijuana to treat some of these illnesses, while Algae Dynamics has been taking a holistic approach by examining specific cannabinoids found in marijuana and combining that research with expertise in extracting various nutritional dietary products, like Omega-3 fatty acids. An article further discussing this topic reads: “Emerging research shows that Omega-3 fatty acids can have very strong interactions with the brain’s natural or biological endocannabinoid system and can also modulate the effects of cannabinoids on the brain. If there is a dietary deficiency of Omega-3 fatty acids, the brain’s natural cannabinoid system is not going to work with optimal efficiency,” Dr. Laviolette explained. “’By contrast, if you can supplement with Omega-3 fatty acids you see certain improvements in the brain’s cannabinoid system, so that immediately got us interested in how synergies between Omega-3 fatty acids and cannabinoids that are derived from marijuana might serve as potential, novel pharmaceutical and nutraceutical products for treating certain specific mental health disorders.’ The brain’s natural cannabinoid system is involved in a lot of different processes that relate to mental health, including mood regulation, one’s ability to learn and remember, and certain cognitive tasks.”
To view the full article, visit http://nnw.fm/gO1sL
About Algae Dynamics Corp.
ADC is engaged in the development of unique health products and pharmaceuticals that utilize hemp, cannabis and algae oils. We have engaged two Canadian universities to provide research into the use of extracts from cannabis oil, which we plan to use to develop products that combine the significant health benefits of Omega-3s derived from algae oil and extracts from cannabis oil. Our research is focused on the use of cannabis oil in the context of cancer, and the use of cannabis derivatives for the development of novel pharmacotherapies for mental health. For more information, visit http://www.algaedynamics.com.
NetworkNewsWire
7 years ago
ADYNF Collaborating with Prominent Neuroscientist to Research Benefits of Cannabis Oil for Mental Health Disorders
- Partnership between Algae Dynamics and Dr. Steven Laviolette focuses on medical benefits of cannabis and hemp oils for various mental health disorders
- Canada is moving to legalize cannabis throughout the country in 2018, which could radically change research playing field
- Canadian cannabis oil extraction market projected to reach $1.5 billion by 2020
Algae Dynamics Corp. (OTCQB: ADYNF), a Canadian company focused on the development of proprietary research and products derived from cannabis and hemp oils, has begun a collaborative relationship with one neuroscientist who is looking deep within the brain for answers to some of the world’s most pressing mental health problems.
This research agreement with Dr. Laviolette, a neuroscientist at the University of Western Ontario, Canada, is no small thing. The level of human misery and the resulting global economic burden caused by neurological and mental health disorders is hard to fathom. The World Health Organization reports that failure to adequately address and provide effective treatment for depression and other anxiety disorders could cost the world $1 trillion each year, according to research published in The Lancet (http://nnw.fm/3kSsX).
“I started working with Algae Dynamics in the spring of this year and it’s going really well, we’re already making quite a bit of progress,” Dr. Laviolette said. “They’re very open-minded and they appreciate the science. They understand the best products come from the best quality science, so I’m very excited to be working with them.”
Algae Dynamics approached Dr. Laviolette, because he was already examining how cannabinoids can treat disorders such as addiction, schizophrenia, depression and post-traumatic stress disorder.
“We’ve been looking at how we can more effectively utilize different chemicals that are found in marijuana to serve as more effective treatments for some of these devastating illnesses,” Dr. Laviolette says. “Algae Dynamics was taking a holistic approach to this research by not only looking at the specific cannabinoids in marijuana, but they also have a background in the extraction of various nutritional dietary products such as Omega-3 fatty acids. That was very exciting for me.”
Emerging research shows that Omega-3 fatty acids can have very strong interactions with the brain’s natural or biological endocannabinoid system and can also modulate the effects of cannabinoids on the brain. If there is a dietary deficiency of Omega-3 fatty acids, the brain’s natural cannabinoid system is not going to work with optimal efficiency, Dr. Laviolette explained.
“By contrast, if you can supplement with Omega-3 fatty acids you see certain improvements in the brain’s cannabinoid system, so that immediately got us interested in how synergies between Omega-3 fatty acids and cannabinoids that are derived from marijuana might serve as potential, novel pharmaceutical and nutraceutical products for treating certain specific mental health disorders.”
The brain’s natural cannabinoid system is involved in a lot of different processes that relate to mental health, including mood regulation, one’s ability to learn and remember, and certain cognitive tasks.
“We know in certain mental health disorders like depression, addiction and schizophrenia, there’s a lot of disturbance in this cannabinoid system,” Dr. Laviolette continued. “So oftentimes people will sort of self-medicate with marijuana and perhaps expose themselves to some of the more negative aspects of it. One compound, in particular, called THC (tetrahydrocannabinol), can have negative effects, especially in younger adults, especially adolescents.”
Dr. Laviolette and his team have been comparing and contrasting THC versus other cannabinoids found in marijuana and seek to answer the question of: “What are some of the molecular pathways that they activate and how can we modulate different phytocannabinoids in their formulations and combine them with Omega-3’s to make them less likely to produce some of the negative side effects possible with marijuana exposure?”
“We’re looking at both the positive and negative effects, with the goal of really reducing or eliminating the negative effects and really sort of amplifying the positive chemicals that are found in marijuana in terms of treating some of these illnesses,” Dr. Laviolette said.
One of the biggest concerns of the medical community, and one reason a lot of doctors are not very willing to prescribe their patients cannabinoids in terms of treating mental health symptoms like PTSD, depression or even schizophrenia, relates to the potential negative side effects, he added.
“What we’re really trying to do is tease apart the positive and negative aspects of marijuana. We’ve been able to show CBD can actually be a promising treatment for a variety of mental health disorders like PTSD and schizophrenia,” Dr. Laviolette said. “It’s quite amazing because, when you think about it, it’s the same plant but these two different, competing chemicals are producing different effects in terms of mental health.”
Another major issue associated with using cannabinoids as a medical treatment is that people “aren’t really too keen on the idea of just smoking cannabinoids,” he said. “So, one of the major research directions we’re taking with Algae Dynamics is coming up with more effective non-smoked formats of medical marijuana, which includes oil-based formulations.”
Algae Dynamics’s focus on supporting research directed at the medical benefits of cannabis and hemp oils is providing a critical lifeline to scientists like Dr. Laviolette.
“The other aspect is that it’s very difficult to do this research because of all the different government regulations that you need to go through to, first; get ahold of the actual compounds, and second; get the actual license to perform these sorts of studies,” he said.
Canada is heading toward legalization of cannabis throughout the country in 2018, which could bode well for the research community, investors and companies like Algae Dynamics.
“People are excited. I think there’s a general feeling that cannabinoids are absolutely going to be an emerging biotechnology in the coming decades,” said Dr. Laviolette. “Companies like Algae Dynamics are actually taking this research seriously and are getting in on the ground floor of the development of effective cannabinoid products.”
While solid, quality research takes time, Dr. Laviolette said his team is now moving toward the clinical realm with the goal of collaborating with clinicians sometime within the next few months. Discovering the ideal ratios of THC and CBD and then combining those with a nutritional supplement such as Omega-3 fatty acids is expected to lead to the best formulations for an early stage clinical trial.
“I think there’s tremendous potential for development of pharmaceuticals and nutraceuticals based on that,” Dr. Laviolette says. “I’ve been doing this research for well over two decades now and what you consistently realize is that the existing drugs available for treating some of these symptoms have some really bad side effects. So, it’s not only the limited effectiveness of a lot of these drugs used to treat depression and anxiety, but the serious side effects that make a lot of people stop taking them. It’s essentially a barrier of sorts to long term treatment.”
Dr. Laviolette’s research is providing early, promising evidence that there are very few side effects associated with cannabidiol, or CBD, which is a non-psychoactive compound in marijuana.
“I think there’s tremendous potential to develop pharmacological treatments that are derived from natural products that are relatively pure. I think they’ll be a much more promising alternative than the more traditional medications that are out there right now,” he added.
Cannabis is a complex plant with well over 100 different phytochemicals, a fact that Dr. Laviolette describes as exciting but also one that means researchers are just barely beginning to “scratch the surface.”
For more information about Dr. Laviolette and his research with Algae Dynamics, visit the company’s website at www.AlgaeDynamics.com
NetworkNewsWire
7 years ago
ADYNF Focuses on Cannabis Oil Vision for Medicinal Applications
- The Canadian cannabis oil extraction market is projected to reach $1.5 billion by 2020
- Algae Dynamics is focused on extracting cannabis and hemp oil, which has a range of medicinal health benefits
- Cannabis oil extracts act on the human endocannabinoid system, which includes receptors in the brain, organs, and tissues
The oils extracted from cannabis plants, especially those with high levels of cannabidiol (CBD), have been used for medicinal purposes for millennia. Algae Dynamics Corp. (OTCQB: ADYNF) has been focused on cannabis oil extraction, part of its vision to become a world leader in this field. A $1 million market in Canada in 2015, the oil extraction market is anticipated to hit $1.5 billion by 2020. Full legalization is expected across the country by July 2018, and research into the Colorado market, one of the first legal cannabis markets in the U.S., has led to estimates of 45 percent of users converting from dried marijuana to extracts and oil. The market value projections are based on similar anticipated trends for the Canadian market.
By extracting the oil from cannabis, the company aims to develop a range of health products from its derivatives. Cannabis oil, according to CBD International (http://nnw.fm/WqF8k), is beneficial for various health conditions and illnesses. The focus is cannabidiol, one of the main ingredients in marijuana. The other is tetrahydrocannabinol (THC), which is responsible for the psychotropic effects of cannabis. On the other hand, CBD does not produce a high and has been used to treat pain and epileptic seizures, as well as to slow the effects of Alzheimer’s disease. Studies have shown CBD to act on the enzymes that form amyloid plaques in the brain, which kill brain cells in people with the disease, with CBD believed to slow down this progression.
Also, CBD has antioxidant effects that can help improve heart health. It can ease pain associated with multiple sclerosis as well. Other effects of cannabis oil include boosting appetite, treating inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis, and inducing a longer, more restful sleep. It’s been used to manage conditions such as anxiety, glaucoma, post-traumatic stress disorder and cancer.
Algae Dynamics Corp. is highly focused on cannabis oil extraction. Complementing it with Omega-3 oils from algae to boost the effectiveness of medicinal cannabis oils, this effort is helping the company take advantage of the traction cannabis has gained for medicinal purposes. This has been the focus of the company’s strategy for 2017, which has included university research agreements, application for a Health Canada license and supplying oil extraction equipment for the built-out oil extraction room at Bonify’s facility (a private Licensed Producer and partner).
The extracts play a significant role in human physiology. There are plant-derived cannabinoids, or phytocannabinoids, and ones produced in the human body, known as endocannabinoids. Known since the 1960s, cannabinoids have demonstrated numerous links to maintaining health. In 1992, the biological endocannabinoid system was discovered, further substantiating this connection. These compounds and their receptors are found in the brain, glands, organs, immune cells and connective tissues, leading to the development of cannabis-based oils with a number of reported health benefits.
As mentioned above, the company recently partnered with Bonify to extract cannabis oils and develop cannabis oil products (http://nnw.fm/qaf6H), with revenue to be generated from the cannabis oils the company extracts at Bonify.
For more information, visit the company’s website at www.AlgaeDynamics.com
NetworkNewsWire
7 years ago
ADYNF Positioned to Benefit as Market Survey Highlights Consumer Preference for CBD
- Survey respondents use CBD to treat anxiety, depression, insomnia and joint pain
- ADYNF is researching impact of cannabidiol products in treatment of mental health issues and cancers
- 61% of consumers surveyed said they are spending greater than $50 monthly on CBD products
Algae Dynamics Corp. (OTCQB: ADYNF) could be among the chief beneficiaries of a recent survey that found that 42% of respondents chose cannabidiol (CBD), derived from hemp or marijuana, and dropped traditional medicines (http://nnw.fm/6Qu2c). In addition, an “Understanding Cannabidiol” survey of some 2,400 members of HelloMD, an online CBD community, and market research firm Brightfield Group jointly found that, by an overwhelming majority, respondents favored CBD made from cannabis rather than industrial hemp (http://nnw.fm/s2m3Q).
CBD is being used instead of traditional medicines to treat anxiety (67%), insomnia (60%), joint pain and inflammation (52%) and depression (43%). A total of 61% of survey-takers said that they spend more than $50 monthly on CBD products, while more than half of respondents said they use oil cartridges and vaping. Notably, more than half (58%) of those surveyed are women.
The study found that 42% of respondents use cannabis rather than traditional medications for depression, anxiety, joint pain and anxiety, and some 80% said they find CBD products to be very or extremely effective treatments. Some 90% said they would be likely to buy marijuana-based CBD-only products.
Also, 53% of CBD users purchase CBD products from storefront dispensaries, 31% through local delivery services, and 17% online. Not only do 29% of this group find that CBD products provide the best medical relief, but, in the study’s words “about 66% of CBD users indicated that CBD products are either more effective or much more effective in relieving their medical conditions than are over-the counter (OTC) products.”
Algae Dynamics, headquartered and doing business in Ontario, Canada, is a development stage company which is publicly traded in the U.S. It maintains university collaborations to develop specific cannabis oil product lines, with the University of Waterloo and the University of Western Ontario. It specializes in cannabis oil extraction and hemp oils.
ADYNF is working with the University of Western Ontario to explore the impact of cannabis oil, its constituents and other botanical extracts that lead to development of unique products for the treatment of mental health issues, such as post-traumatic stress disorder, anxiety, depression, and schizophrenia.
With the University of Waterloo, ADYNF is performing fundamental research on cannabis oil leading to the treatment of cancers of the pancreas, breast, prostate and colorectum. ADYNF is seeking to combine the benefits of algae and cannabis oils and their role in the cancer-related potential treatment by botanical oils, specifically focusing on cannabis.
For more information, visit the company’s website at www.AlgaeDynamics.com
NetworkNewsWire
7 years ago
ADYNF Poised to Profit from Impending Recreational Cannabis Legalization
Cannabis is America’s fastest-growing industry, predicted by Forbes to grow as much as 700 percent by the year 2020. Canada-based Algae Dynamics Corp. (OTCQB: ADYNF) is working to exploit a niche market in Canada’s cannabis space as the Canadian government works to implement blanket legalization of marijuana by 2018. As noted in a recent NNW article:
“Algae Dynamics is focused on the extraction of oils from hemp, cannabis and algae for use in unique health products and pharmaceuticals. The company has already engaged two highly respected universities to provide research into the various uses of cannabis and hemp oil extracts, which, in combination with other compounds, may prove effective in treating cancers of the colon-rectum, pancreas, breast and prostate, as well as for the development of novel pharmacotherapies for various mental health maladies. With medical marijuana already legal in Canada, Algae Dynamics is carving out a lucrative niche in an explosive market and is positioned to succeed. However, the legalization of recreational marijuana could propel the company far beyond what one would normally expect.”
To view the full article, visit http://nnw.fm/Jyc3S
About Algae Dynamics Corp.
ADC is engaged in the development of unique health products and pharmaceuticals that utilize hemp, cannabis and algae oils. We have engaged two Canadian universities to provide research into the use of extracts from cannabis oil, which we plan to use to develop products that combine the significant health benefits of Omega-3s derived from algae oil and extracts from cannabis oil. Our research is focused on the use of cannabis oil in the context of cancer, and the use of cannabis derivatives for the development of novel pharmacotherapies for mental health. For more information, visit http://www.algaedynamics.com.
NetworkNewsWire
7 years ago
ADYNF Creating a Lucrative Niche Opportunity
- Cannabis is fastest-growing industry in North America
- Canada’s cannabis market is ripe for explosive growth
- Algae Dynamics carving out niche in explosive market
The fastest-growing industry with the most consistent growth rate in North America is legal marijuana. A recent Forbes article says that the market could grow 700% by 2020 (http://nnw.fm/5lE7h). Investors have become acutely aware, which explains the movement in some marijuana stocks that have risen dramatically over the last 18 months.
According to ArcView, a well-known cannabis research firm, North American sales of legal medical and recreational cannabis soared 34% in 2016 to $6.9 billion. These markets are expected to continue to grow at a blistering pace of over 25 percent annually through 2021, reaching approximately $22 billion. Growth is expected to come from further jurisdictional expansion of legalization, plus rapid organic growth in areas where the drug is already legal. Mexico recently legalized medical cannabis throughout the country, and, in Canada, the number of eligible medical patients has been growing at a pace of almost 10% per month, according to Health Canada. Canada’s government has also introduced legislation to make recreational marijuana legal across the country by this time next year.
A professional consulting group hired to assess Canada’s proposed recreational marijuana market says that jurisdictions that regulate cannabis should expect “unbelievably high” sales growth in the first few years as criminals are driven out of business (http://nnw.fm/6wB6B). Not yet authorized to discuss findings on future Canadian cannabis markets because of contracts with Health Canada, a look at the group’s estimates for Colorado’s regulated cannabis industry suggests that Canada can expect its own markets to generate billions of dollars per year in direct and indirect economic activity. While every jurisdiction is different, Canada’s population is seven times larger than that of Colorado, where regulated marijuana sales skyrocketed 42 percent between 2014 and 2015 and totaled nearly $1 billion. Numbers out of Canada could easily be seven to 10 times as much as Colorado.
Many of the better known marijuana stocks have already moved in anticipation of the forthcoming windfall of business. The way to make money on this incoming avalanche of revenues is to find and exploit a niche market, which is exactly what Algae Dynamics Corp. (OTCQB: ADYNF) is in the midst of undertaking. Algae Dynamics is focused on the extraction of oils from hemp, cannabis and algae for use in unique health products and pharmaceuticals. The company has already engaged two highly respected universities to provide research into the various uses of cannabis and hemp oil extracts, which, in combination with other compounds, may prove effective in treating cancers of the colon-rectum, pancreas, breast and prostate, as well as for the development of novel pharmacotherapies for various mental health maladies.
With medical marijuana already legal in Canada, Algae Dynamics is carving out a lucrative niche in an explosive market and is positioned to succeed. However, the legalization of recreational marijuana could propel the company far beyond what one would normally expect. One would suspect the company of being prepared with product and processes to profit from recreational legalization as well. Cannabis sales in Colorado soared 42 percent in the year recreational use was allowed. Canada’s cannabis markets and Algae Dynamics’ endeavors could hit some amazing numbers and exceed even that eye-popping growth rate.
For more information, visit the company’s website at www.AlgaeDynamics.com
NetworkNewsWire
7 years ago
ADYNF Hoping US Senate Bill Decriminalizing Marijuana Will Be Successful
- Proposed legislation would remove cannabis from the list of Schedule I controlled substances.
- If successful, it would pave the way for the Canadian company to enter the U.S. market.
- Unique combination of algae and cannabis oils targeting cancer and mental health disease, making Algae Dynamics a lucrative opportunity for investors.
A bill looking to decriminalize marijuana all over the country has recently been introduced in the U.S. Senate, giving fresh hope to legal cannabis businesses that they will be able to expand operations and access federal protections and banking solutions. The bill, titled the Marijuana Justice Act, was introduced by New Jersey Democrat Senator Cory Booker, being designed to reverse the tough federal stance on cannabis and hopefully resolve the ongoing conflict between federal and state laws on cannabis. While still classified as a Schedule I drug on par with heroin, cocaine and LSD at the federal level, marijuana is already legal in 29 states and the District of Columbia either for medical or recreational use. If successful, the bill would allow companies such as Algae Dynamics Corp. (OTCQB: ADYNF) to operate freely in the United States in an entirely legal and regulated market.
The Marijuana Justice Act would remove cannabis from the federal list of drugs on the Controlled Substances Act, according to the Investing News Network (http://nnw.fm/njp9W). The bill would incentivize states that still oppose marijuana legalization to update their legislation and would also allow prisoners serving a sentence on marijuana possession charges to ask for resentencing.
In a statement, Booker explained that his bill is aimed at helping the current “broken” state of U.S. drug laws. Instead of making communities safer, current drug laws waste billions in taxpayer money, diverting resources from fighting violent crimes and tearing families apart, with an unfair impact on low-income communities and communities of color, the statement said.
Supporters of decriminalization expect tough opposition to the bill, with known opponent Attorney General Jeff Sessions currently seeking Congressional support to remove protections on medical marijuana use at state level and to get a targeted look at MMJ users.
Analysts think the bill is unlikely to pass at this time, but are optimistic that it will stimulate a conversation in Congress on the topic. Cannabis financial analyst Alan Brochstein voiced hope that Senator Booker’s bill would at least get lawmakers to focus on some of the issues the industry is facing – most notably the absence of federal banking support and the lack of sufficient research. But if the bill is successful, it would catapult an already booming industry and open capital markets by removing a series of impediments currently blocking the market, such as access to banking, interstate transport and research, Brochstein said.
The federal decriminalization of marijuana would allow Algae Dynamics Corp., based in Canada but publicly traded in the U.S., to enter the American market with its unique product line that combines the health benefits of algae, hemp and cannabis oils. The U.S. cannabinoid market is expected to reach $2 billion in sales by 2020 and an impressive $50 billion by 2029, according to Statista figures (http://nnw.fm/Uw7he). This would provide Algae Dynamics with ample opportunities to successfully market its innovative blend of algae and cannabis oils, making the company an ideal target for investors in the fast-growing cannabinoid and cannabis industries. For the time being, the company operates only in Canada, where the marijuana oil extraction market is projected to grow exponentially, from C$1 million in 2015 to approximately C$1.7 billion in 2020, with full cannabis legalization expected in the country in 2018.
Algae Dynamics Corp.’s health and pharmaceutical products primarily target cancer and mental ailments, and the company has already partnered with two Canadian universities to research the use of cannabis oil in these fields. The company has signed a three-year, C$600,000 partnership with the university of Waterloo to research the effects of cannabis oils on pancreatic, colorectal, prostate and breast cancer, and a four-year, C$1 million research agreement with the University of Western Ontario to assess the use of cannabis derivatives for mental health diseases including anxiety, PTSD, depression and schizophrenia.
For more information about the company and its innovative products, visit www.AlgaeDynamics.com
NetworkNewsWire
7 years ago
ADYNF Targets Smokeless Medical Cannabis Market, Partners with Major Universities for Research
- Good investment opportunities exist in the marijuana boom, but caution is urged
- Choosing companies with access to the legal medical marijuana space can help investors avoid the risk of changing regulations
- Algae Dynamics Corp. is focusing on cannabis oil extraction and medicine delivery systems to provide the medical benefits without having to smoke
- ADYNF is partnering with two major universities to research the use of cannabis oil extracts for cancers and novel mental health treatments
Everyone knows there is money to be made in marijuana these days. Americans already spend more on cannabis than ice cream each year, and Canadians are anticipating a combined market that may be larger than the entire domestic alcohol industry by 2020.
How and where to invest, however, is not that simple. An article titled “Investing in International Cannabis Markets” in CannaTech (http://nnw.fm/c4bhR) offers some advice to potential investors.
Savvy investors should keep several things in mind. Regulations are changing, and, while the general trend is toward legalization, it is best to look for companies operating in the legal medical marijuana market to avoid the risk of uncertain federal regulations. These types of investments are even better if the company is positioned to take advantage of recreational legalization, when and if it comes.
Algae Dynamics Corp. (OTCQB: ADYNF) is one such company focusing on the extraction of oils from hemp, cannabis and algae for use in unique health products and pharmaceuticals.
Algae Dynamics’ strategy initiative is to explore compounds extracted from cannabis and to focus on the development and formulation of products that combine the benefits of algae and cannabis oils. The company is targeting the human endocannabinoid system with algae and cannabis oil extracts. Endocannabinoids are found naturally in the human body.
The endocannabinoid system plays an essential mediating role in several physiologic systems, and receptors can be found throughout the central and peripheral nervous systems. Plant-based cannabinoids may offer a more natural way of treating various diseases including multiple sclerosis, arthritis, hypertension, memory loss, pediatric epilepsy and neuropathic pain (http://nnw.fm/vXU7K).
Algae Dynamics plans to leverage its expertise in algae oil extraction to produce cannabis oil extracts for use in non-smoke formulations that offer the health benefits of cannabis without the dangers of smoking. Once extracted, cannabis oil can be vaporized or made into tinctures.
Medically beneficial cannabis oil formulations are being researched by Algae Dynamics by way of partnerships with two major universities. The company has signed a research and product development agreement with the University of Waterloo (http://nnw.fm/NLy8a) for a three-year, $600,000 program to investigate the use of cannabis oil in the treatment of colorectal, pancreas, breast and prostate cancers.
A four-year, C$1,000,000 agreement with the University of Western Ontario (http://nnw.fm/A2wdw) will fund research and product development on the use of cannabis derivatives as novel pharmacotherapies for mental health diseases such as depression, post-traumatic stress disorder, anxiety and schizophrenia.
With its entry into the North American cannabinoid market, which is expected to top $2 billion in consumer sales by 2020, Algae Dynamics is an intriguing investment opportunity for those seeking opportunities in this booming market.
For more information, visit the company’s website at www.AlgaeDynamics.com
NetworkNewsWire
7 years ago
ADYNF Developing Potential Breakthrough Fortified Formulas to Boost Human Endocannabinoid System
As debates continue over the legalization of marijuana, many individuals who have never touched plant-derived cannabinoids (phytocannabinoids) do not realize that their bodies naturally produce endocannabinoids, which play an essential mediating role in various human physiologic systems. Recent studies have shown that the production of endocannabinoids is boosted by fatty acids, and Algae Dynamics (OTCQB: ADYNF) has begun developing fortified formulas of omega-3s and cannabis oil that could potentially boost the function of the human body’s endocannabinoid system.
“The products under development by Algae Dynamics promise to pack a powerful therapeutic punch, combining the virtues of omega-3s and cannabinoids. Algae Dynamics’ algae omega-3 oil has a high concentration of DHA, which is in demand by the growing multi-billion dollar food and beverage and health care sectors. The North American omega-3 market was estimated to be $4.0 billion in 2013 and is expected to reach $5.9 billion by 2019, growing at a CAGR of 6.5% from 2014 to 2019. Supplements are the largest application segment driving North America’s omega-3 market, and the cannabinoid market is just as vibrant. It is expected to cross $2 billion in consumer sales by 2020. It seems no matter which market Algae Dynamics chooses for its products, success is almost guaranteed.”
To view the full article, visit http://nnw.fm/rtSN4
About Algae Dynamics
Algae Dynamics is engaged in the development of unique health products and pharmaceuticals that utilize hemp, cannabis and algae oils. To assist in this development, Algae Dynamics engaged two Canadian universities to provide research, focusing on the use of cannabis oil in the context of cancer and the use of cannabis derivatives for the development of novel pharmacotherapies for mental health. Algae Dynamics intends to utilize this research to develop products that combine the significant health benefits of Omega-3 fatty acids derived from algae oil with extracts from cannabis oil for the rapidly growing medical and non-medical markets in Canada and globally. The company has developed strategic relationships with licensed producers of cannabis to ensure a source of cannabis oil. Algae Dynamics’ product development efforts are designed in the near-term for over-the-counter nutraceuticals, and in the longer-term for patented medicines. The company’s recent initiatives are an extension of its previous plan, which was focused solely on commercialization of its proprietary BioSilo® algae cultivation system for the high volume, low cost production of pure contaminant-free algae biomass which is high in Omega-3 fatty acids. For more information, visit the company’s website at http://www.algaedynamics.com.
NetworkNewsWire
7 years ago
ADYNF Therapeutic Fortified Formulas Likely to Boost Endocannabinoid System
- Commercializing proprietary BioSilo® algae cultivation system
- Developing therapies that combine omega-3s and cannabinoids
- Poised to enter billion dollar markets
If you think you haven’t had cannabinoids because you’ve never used cannabis, you are completely mistaken. You may not have ‘touched’ plant-derived cannabinoids (phytocannabinoids), but it would have been biologically impossible to escape the ones produced by your body (endocannabinoids). Endocannabinoids play an essential mediating role in a number of human physiologic systems. They promote a Goldilocks internal environment, a mean between excess and deficiency in a variety of functions and areas, and recent scholarship has shown that their production is enhanced and fostered by fatty acids, the kind used by Algae Dynamics Corp. (OTCQB: ADYNF). As a result, ADYNF has begun to develop fortified formulas of omega-3s and cannabis oil that may boost the functioning of the human endocannabinoid system.
Discovery of what is now known as the endocannabinoid system has a peculiar history. It is perhaps the only known human physiologic system that is named after a plant, and that’s all because of chronology. A number of substances isolated from the cannabis plant were later found to be produced by the human body. First identification and isolation of the two major cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), is attributed to Raphael Mechoulam and his colleague Y. Gaoni in Israel in 1964. Mechoulam, whose discovery and further research into cannabis has earned him the moniker, ‘Father of Cannabis’, was also part of a team that, in 1992, discovered the endocannabinoid system.
This physiologic system plays a vital role in maintaining human health. Endocannabinoids and their receptors permeate the human body. They can be found in the brain, in various organs, in connective tissue, in glands and in immune cells. Their main function appears to be stabilizing our internal environment, freeing it from the dangerous volatility of the external world. Currently, the two best understood endocannabinoids are anandamide and 2-arachidonoylglycerol (2-AG), studies of which have uncovered a number of medical benefits they may have. Anandamide, for example, inhibits the proliferation of breast cancer cells and appears to retard the memory decline associated with Alzheimer’s disease. These encouraging findings suggest that phytocannabinoids offer a ‘natural’ way to treat a variety of ailments, including multiple sclerosis (MS), arthritis, hypertension, memory loss, pediatric epilepsy and neuropathic pain.
Research into cannabis and development of therapeutic products goes on. In Canada, as legalization looms, industry professionals are divided on whether there should be a legal distinction between medical and recreational cannabis. A recent article on CBC News Health reports comments by two researchers, who believe that medicinal and recreational cannabis should be separate (http://nnw.fm/2OzjU). They argue that a dual-stream approach would decrease the stigma associated with cannabis use for medicinal purposes, since, for example, it would be sold at a pharmacy rather than a general retailer. Dual-stream would also protect ‘the supply of strains of medical cannabis that have desirable effects for patients, such as lower THC strains sometimes used to treat children who suffer from seizures’ and also increase clinical research into the therapeutic benefits of cannabis.
The products under development by Algae Dynamics promise to pack a powerful therapeutic punch, combining the virtues of omega-3s and cannabinoids. Algae Dynamics’ algae oil is high in omega-3s DHA/DPA, which is in demand by the growing multi-billion dollar food and beverage and health care sectors. The North American omega-3 market was estimated to be $4.0 billion in 2013 and is expected to reach $5.9 billion by 2019, growing at a CAGR of 6.5% from 2014 to 2019. Supplements are the largest application segment driving North America’s omega-3 market, and the cannabinoid market is just as vibrant. It is expected to cross $2 billion in consumer sales by 2020. It seems no matter which market Algae Dynamics chooses for its products, success is almost guaranteed.
For more information, visit the company’s website at www.AlgaeDynamics.com
NetworkNewsWire
7 years ago
ADYNF is Developing Therapies that Offer Safer Delivery of Cannabinoids
- Focused on cannabis oil product development
- Collaborating with Universities of Waterloo & Western Ontario in R&D
- Strategy to capture market share of non-smoke MMJ products
For MMJ patients who don’t want to take up smoking, Algae Dynamics Corp. (OTCQB: ADYNF) is developing non-smoking delivery systems for cannabinoids. The company aims to produce new formulations of algae and cannabis oils that deliver health benefits without the attendant dangers that result from smoking.
Smoking is a killer. Statistics published by the Centers for Disease Control and Prevention (CDC) estimate that ‘cigarette smoking kills more than 480,000 Americans each year, with more than 41,000 of these deaths from exposure to secondhand smoke’ (http://nnw.fm/fjLk5). Smoking–related illness costs the U.S. economy ‘more than $300 billion a year, including nearly $170 billion in direct medical care for adults and $156 billion in lost productivity’. Yet, tobacco use is a preventable cause of death and disease, which the 15 percent of the population who smoke can avoid, and many would do so if they are presented with non-smoking ways to use tobacco or cannabis.
Luckily, there is more than one way to skin the cannabis cat, for not only can it be smoked but it can be vaporized, and its oil can be extracted or tinctures may be made from it. Smoking is, undoubtedly, a common method of delivery. The simplest way of using cannabis is burning and smoking the (female) inflorescence. The flowers and buds of female plants contain the highest concentrations of cannabinoids, while male flowers contain much less. Leaves of both genders contain cannabinoids and may be mixed with the inflorescence to be smoked. Extracts from the plant are also processed to produce hashish, for example, which tends to be smoked as well. Cannabis is sometimes heated to produce a vapor that can be inhaled or the inflorescence may be immersed in a solvent, such as alcohol, to produce a tincture rich in cannabinoids.
The Algae Dynamics Corp. way, however, is the extraction of the oils from cannabis. In December 2016, the company announced a new oil extraction initiative in the Canadian cannabis industry (http://nnw.fm/8dQkw). It plans to deploy its existing extraction technology of algae oil to cannabis. To supplement this initiative, ADYNF is expanding its research and product development (R&D) partnerships with Canadian academia, planning to sign supply, service and sales agreements with existing Access to Cannabis for Medical Purposes Regulations (ACMPR) licensed producers, and the company plans to submit an application to become a producer and seller of medical marijuana under the ACMPR.
The cannabis oil extraction industry is expected to hit C$1.7 billion by 2020. This exponential growth will, in part, be propelled by a desire for cannabinoid delivery methods that do not involve smoking. A study by Mackie Research Capital found that 45 percent of dried marijuana users in Colorado State would eventually convert to marijuana extracts and oils. If that is indicative of cannabis use generally, then ADYNF’s safer delivery methodology is soon likely to be very much in demand.
For more information, visit the company’s website at www.AlgaeDynamics.com
NetworkNewsWire
7 years ago
ADYNF Featured in Exclusive Audio Interview by NetworkNewsWire
Multifaceted financial news and publishing company NetworkNewsWire (“NNW”) this morning announced the online availability of an exclusive audio interview with Algae Dynamics Corp. (OTC: ADYNF). In the interview, Paul Ramsay, president and chairman of Algae Dynamics, provides insight into the company’s operational focus on the development of unique health products and pharmaceuticals utilizing cannabis, hemp and algae oils. “We’re working with cannabis in isolation, but we are also formulating different combinations of algae mixed with cannabis oils. It’s quite an interesting program and quite exciting given the health benefits,” Ramsay noted. “We’re doing this because we have a lot of background with algae oil extraction. We have a lot of expertise, and we are rolling that into the cannabis oil extraction field. We are also combining the algae and the cannabis oil because it enhances the efficacy of treatment of the benefit of cannabis oils. There [is] a lot of research done, and we think [our team] will make some big strides in that area.” Ramsay concludes the interview by discussing Algae Dynamics’ strategy for sustainable growth, including its planned entry into the rapidly-evolving Canadian cannabis market. The full interview can be heard at http://nnw.fm/XWaE0.
To view the full press release, visit http://nnw.fm/Pq0wD
About Algae Dynamics
Algae Dynamics is engaged in the development of unique health products and pharmaceuticals that utilize hemp, cannabis and algae oils. To assist in this development, Algae Dynamics engaged two Canadian universities to provide research, focusing on the use of cannabis oil in the context of cancer and the use of cannabis derivatives for the development of novel pharmacotherapies for mental health. Algae Dynamics intends to utilize this research to develop products that combine the significant health benefits of Omega-3 fatty acids derived from algae oil with extracts from cannabis oil for the rapidly growing medical and non-medical markets in Canada and globally. The company has developed strategic relationships with licensed producers of cannabis to ensure a source of cannabis oil. Algae Dynamics’ product development efforts are designed in the near-term for over-the-counter nutraceuticals, and in the longer-term for patented medicines. The company’s recent initiatives are an extension of its previous plan, which was focused solely on commercialization of its proprietary BioSilo® algae cultivation system for the high volume, low cost production of pure contaminant-free algae biomass which is high in Omega-3 fatty acids. For more information, visit the company’s website at http://www.algaedynamics.com
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Renee
5 years ago
Hot Features
Premium
